Opthea
Suite 0403, Level 4, 650 Chapel Street
South Yarra
Victoria
3141
Tel: 613-9826-0399
Website: http://www.opthea.com/
Email: info@opthea.com
95 articles about Opthea
-
Opthea strengthens its Board of DirectorsElects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of Shareholders
4/22/2022
Opthea Limited today announced the appointment of Mr. Quinton Oswald and Dr. Susan Orr to its Board of Directors, effective immediately following election at a General Meeting of Shareholders on April 21st , 2022.
-
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference
3/10/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at Oppenheimer’s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022.
-
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer
3/2/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Dr. Joel Naor as Chief Medical Officer, effective 1 March 2022.
-
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
2/14/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.
-
Opthea To Present at SVB Leerink Global Healthcare Conference
2/10/2022
Opthea Limited announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022.
-
Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference
2/9/2022
Opthea Limited announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022.
-
Opthea Receives A$6.6 m R&D Tax Incentive
1/24/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received a A$6.6 million research and development tax credit from the Australian Taxation Office.
-
Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference
1/4/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the H.C. Wainwright BIOCONNECT Conference, being held virtually from January 10-13, 2022.
-
Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD
1/3/2022
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Ms. Judith Robertson as the Company’s first Chief Commercial Officer, effective 1 January 2022.
-
Opthea Granted Chinese Patent Covering OPT-302
10/26/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the grant of Chinese Patent Number 106414487 B covering OPT-302, its soluble VEGFR-3 “trap” molecule currently being investigated in two global Phase 3 registrational clinical trials, ShORE and COAST.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
10/19/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that the first clinical trial sites in the Asia-Pacific region are now open for patient enrollment into the OPT-302 Phase 3 pivotal clinical program for the treatment of wet age-related macular degeneration.
-
Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302
10/4/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that enrollment for its Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration is now open in Europe.
-
Opthea To Present at September 2021 Investor Conferences
9/2/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the following investor conferences in September:
-
Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights
8/30/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, reported financial results for the year ended June 30, 2021 and provided an overview of recent progress and accomplishments.
-
Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference
8/10/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Ophthalmology Virtual Conference being held August 17, 2021.
-
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
8/9/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration.
-
Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration
7/6/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce that the U.S. Food and Drug Administration has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with neovascular age-related macular degeneration.
-
Opthea Appoints Company Secretary and Vice President of Finance
6/14/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mrs. Karen Adams as Vice President of Finance and Company Secretary, effective June 12, 2021.
-
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
6/1/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointments of Dr. Julia Haller and Ms. Judith Robertson as independent Non-Executive Directors to its Board of Directors, effective June 1, 2021.